2024-516063-89-00Active, not recruitingPhase 3
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Oct 2026
Brief summary (registry, in English)
In the RAS G-12 population (referred to as RAS G12 population): To compare the effect of treatment with RMC-6236 versus Investigator’s choice of standard therapy on: PFS OS
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- First submitted
- 13 Sept 2024
- Start date
- 10 Apr 2025
- Lead sponsor
- Revolution Medicines Inc.
- Diseases
- Pancreatic cancer
- EU CT number
- 2024-516063-89-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 136
- 16 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior therapy with any direct RAS-targeted therapy (eg, degraders and/or inhibitors).
- Major surgery within 4 weeks prior to randomization.
Other illness
- History of or known central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study treatment.
Other
- Patient is unable or unwilling to comply with all protocol-required study visits or procedures.
Who the study is looking for
- At least 18 years of age and has provided informed consent. Follow local regulatory requirements if the legal age of consent for study participation is >18 years old.
- ECOG performance status 0 or 1.
- Histologically or cytologically confirmed PDAC with metastatic disease
- Measurable disease per RECIST 1.1
- Adequate organ function (bone marrow, liver, kidney, coagulation)
- One prior line of systemic therapy in the metastatic setting.
- Documented RAS mutation status, either mutant or wild-type. RAS mutations are defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
- Able to take oral medications
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR | Berlin | Germany | Active, not recruiting |
| Universitaetsklinikum Heidelberg AöR | Heidelberg | Germany | Active, not recruiting |
| Klinikum der Universitaet Muenchen AöR | Munich | Germany | Active, not recruiting |
| Universitaetsklinikum Ulm AoR | Ulm | Germany | Active, not recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Active, not recruiting |
| Clínica Universidad de navarra | Pamplona | Spain | Active, not recruiting |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | Active, not recruiting |
| Institut Paoli-Calmettes | Marseille | France | Active, not recruiting |
| Centre De Lutte Contre Le Cancer Eugene Marquis | Rennes Cedex | France | Active, not recruiting |
| Institut Gustave Roussy | Villejuif | France | Active, not recruiting |
| Hopital Paul Brousse | Villejuif Cedex | France | Active, not recruiting |
| Istituto Europeo di Oncologia s.r.l | Milan | Italy | Active, not recruiting |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Active, not recruiting |
| Istituto Oncologico Veneto | Padova | Italy | Active, not recruiting |
| Azienda Ospedaliero Universitaria Pisana | Pisa | Italy | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.